… proof of concept, and the availability of well-defined clinical endpoints. AX-0810 for Cholestatic Diseases … intends to advance AX-1412 targeting B4GALT1 to early clinical proof of concept stage, then would seek to partner … AX-0810 targeting NTCP and AX-1412 targeting B4GALT1 into clinical development in late 2024/early 2025. Upcoming …
… AX-0810 targeting NTCP and AX-1412 targeting B4GALT1 into clinical development in late 2024/early 2025. Financial … intends to advance AX-1412 targeting B4GALT1 to early clinical proof of concept stage, then would seek to partner … continued investment in it, as well as the timing of our clinical development, the potential of our technologies and …
… plans to discuss findings from sepofarsen Illuminate trial with regulators and provide an update in Q3/early Q4; … delivery approaches. The Company will present further non-clinical data for Axiomer and announce its internal … there are no pharmaceutical treatments approved or in clinical development that treat the vision loss associated …
… and Financial Results Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy … delivery approaches. The Company will present further non-clinical data for Axiomer and announce its internal … there are no pharmaceutical treatments approved or in clinical development that treat the vision loss associated …
… 2023 strategy, which includes starting the Phase 2/3 trial for sepofarsen in LCA10 patients, initiating the … benefit patients with unmet medical needs based on early clinical data coupled with non-clinical data. Through PRIME, … in R&D expenses was primarily due to initiation of the clinical trials for sepofarsen and QR421a in 2019 and …
… progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 … Usher syndrome type 2A exon 13; on track to report first clinical data for QR-421a in late Q1 2020 Initiated a … Reported positive top-line results from the Phase 1/2 clinicaltrial. In the trial, sepofarsen was observed to be …
… Ophthalmology and has been involved in numerous global clinical trials for patients with inherited retinal diseases … IRD genes. He is currently the PI on seven different human clinical trials in Montreal, testing the safety and efficacy …
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).